These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 27331286)
1. Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope? Ingelfinger JR; Rosen CJ N Engl J Med; 2016 Jul; 375(4):380-2. PubMed ID: 27331286 [No Abstract] [Full Text] [Related]
2. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease. Wanner C Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892 [No Abstract] [Full Text] [Related]
3. London buses: A cardiovascular outcome trial equivalent? Grant PJ Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327 [No Abstract] [Full Text] [Related]
9. Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide. Lingvay I; Leiter LA Circulation; 2018 May; 137(21):2200-2202. PubMed ID: 29784677 [No Abstract] [Full Text] [Related]
10. [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?]. Scheen AJ; Paquot N Rev Med Liege; 2018 Jan; 73(1):43-50. PubMed ID: 29388411 [TBL] [Abstract][Full Text] [Related]
11. Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus. Patoulias D; Eid AH; Rizzo M J Diabetes Complications; 2023 Dec; 37(12):108630. PubMed ID: 39034649 [No Abstract] [Full Text] [Related]
12. [Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality]. Zechmann S Praxis (Bern 1994); 2016 Mar; 105(6):349-50. PubMed ID: 26980688 [No Abstract] [Full Text] [Related]
13. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Zinman B; Lachin JM; Inzucchi SE N Engl J Med; 2016 Mar; 374(11):1094. PubMed ID: 26981940 [No Abstract] [Full Text] [Related]
14. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Rosenstein R; Hough A N Engl J Med; 2016 Mar; 374(11):1093-4. PubMed ID: 26981944 [No Abstract] [Full Text] [Related]
15. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Edwards JL N Engl J Med; 2016 Mar; 374(11):1093. PubMed ID: 26981943 [No Abstract] [Full Text] [Related]
16. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Fischereder M; Schönermarck U N Engl J Med; 2016 Mar; 374(11):1092-3. PubMed ID: 26981942 [No Abstract] [Full Text] [Related]
17. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Sarafidis PA; Tsapas A N Engl J Med; 2016 Mar; 374(11):1092. PubMed ID: 26981941 [No Abstract] [Full Text] [Related]
18. Cardiovascular Risk and Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes. Ingelfinger JR; Rosen CJ N Engl J Med; 2015 Nov; 373(22):2178-9. PubMed ID: 26605932 [No Abstract] [Full Text] [Related]
19. Preventing cardiovascular events with empagliflozin: at what cost? Naci H; Basu S; Yudkin JS Lancet Diabetes Endocrinol; 2015 Dec; 3(12):931. PubMed ID: 26590682 [No Abstract] [Full Text] [Related]